In models of human breast cancer, inhibition of YB-1 with a dominant negative mutant (interferes with the DNA binding activity of the protein [S102A]) slows tumor cell growth [15], and this is associated with the downregulation of EGFR and HER-2 [9]. Here, ERBB2 is linked to neoplasm.